Literature DB >> 10496285

Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma.

N A Paleologos1, D R Macdonald, N A Vick, J G Cairncross.   

Abstract

The authors reviewed the results of neoadjuvant (preradiation) procarbazine, CCNU, and vincristine chemotherapy for anaplastic oligodendrogliomas because, increasingly, chemotherapy is prescribed before radiation for oligodendroglial neoplasms. The data indicate that 70% of patients respond to neoadjuvant chemotherapy, whereas 30% require early radiation because they either have chemoresistant tumors or experience unacceptable chemotoxicity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10496285     DOI: 10.1212/wnl.53.5.1141

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  20 in total

Review 1.  Response of low-grade oligodendroglial tumors to temozolomide.

Authors:  Thomas N Byrne
Journal:  J Neurooncol       Date:  2004-12       Impact factor: 4.130

Review 2.  PCV chemotherapy for oligodendroglioma: response analyzed on T2 weighted-MRI.

Authors:  S Diabira; M C Rousselet; E Gamelin; P Soulier; E Jadaud; P Menei
Journal:  J Neurooncol       Date:  2001-10       Impact factor: 4.130

3.  Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas.

Authors:  A Boiardi; M Eoli; A Salmaggi; B Pollo; I Milanesi; G Broggi; A Silvani
Journal:  J Neurooncol       Date:  2000-08       Impact factor: 4.130

4.  Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation.

Authors:  S E Combs; R Ahmadi; D Schulz-Ertner; C Thilmann; J Debus
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

5.  High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.

Authors:  Lauren E Abrey; Barrett H Childs; Nina Paleologos; Lynne Kaminer; Steven Rosenfeld; Donna Salzman; Jonathan L Finlay; Sharon Gardner; Kendra Peterson; Wendy Hu; Lode Swinnen; Robert Bayer; Peter Forsyth; Douglas Stewart; Anne M Smith; David R Macdonald; Susan Weaver; David A Ramsey; Stephen D Nimer; Lisa M DeAngelis; J Gregory Cairncross
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

6.  A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.

Authors:  Nimish A Mohile; Peter Forsyth; Douglas Stewart; Jeffrey J Raizer; Nina Paleologos; Tarun Kewalramani; David N Louis; J Gregory Cairncross; Lauren E Abrey
Journal:  J Neurooncol       Date:  2008-05-06       Impact factor: 4.130

7.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

Review 8.  The role of chemotherapy for pure and mixed anaplastic oligodendroglial tumors.

Authors:  Erin M Dunbar
Journal:  Curr Treat Options Oncol       Date:  2009-04-18

9.  Posterior fossa oligodendroglioma.

Authors:  Naveen Chitkara; Rakesh Chanda; Anil K Thakur; Seema Chanda; N K Sharma
Journal:  Indian J Pediatr       Date:  2002-12       Impact factor: 1.967

10.  Role of exclusive chemotherapy as first line treatment in oligodendroglioma.

Authors:  Marie Pierre Sunyach; Anne Jouvet; David Perol; Emmanuel Jouanneau; Jacques Guyotat; Laurence Gignoux; Christian Carrie; Didier Frappaz
Journal:  J Neurooncol       Date:  2007-06-14       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.